ICU Medical stock faces an 18.29 percent gap to USD 192.80 target

Published on 10/17/2026 at 20:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Adjusted earnings per share guidance rose to USD 8.60-9.00 on August 6, 2026. ICU Medical stock costs USD 162.99 on October 16, 2026, down 2.54 percent on Nasdaq.

Consensus target and next results

MarketBeat reported a USD 192.80 average target from nine analysts on October 5, 2026, 18.29 percent above the stock price.
ICU Medical raised adjusted earnings per share guidance to USD 8.60-9.00 on August 6, 2026.
ICU Medical stock stood at USD 162.99 on Nasdaq on October 16, 2026 at 4:00 p.m. EDT, down 2.54 percent versus the prior close of October 15, 2026.
ICU Medical is expected to report its next results on November 5, 2026.

ICUI, US44930G1076, Illustration mit AI erstellt.

On October 5, 2026, MarketBeat reported a USD 192.80 average 12-month target from nine analysts for ICU Medical. Against the October 16 Nasdaq closing price of USD 162.99, that target stands 18.29 percent higher. The stock finished at USD 162.99 at 4:00 p.m. EDT, down 2.54 percent from the prior Nasdaq close.

Guidance points to higher earnings

ICU Medical raised and narrowed its fiscal-year 2026 adjusted earnings per share guidance to USD 8.60-9.00 on August 6, 2026, according to the Yahoo Finance transcript. The same call put adjusted EBITDA guidance at USD 415 million-435 million and described adjusted gross margin of 41.00 percent for the full year.

Stock remains below its yearly high

The October 16 close was USD 29.86 below ICU Medical's 52-week high of USD 192.85 and 15.49 percent below that level. The 52-week low was USD 113.37, leaving the stock 43.68 percent above the bottom of the range. ICU Medical was up 14.20 percent year to date, while volume reached 221,673 shares against an average of 273,071.

Valuation and reporting date

ICU Medical carried a market capitalization of USD 4.1 billion and a trailing P/E ratio of 136.97 on October 16, 2026. The next earnings date is November 5, 2026, according to MetaCap, which lists a consensus earnings-per-share estimate of USD 1.75 for that report.

Comparison with peers

ICUI (Nasdaq, USD): minus 2.54 percent, P/E 138.13, market capitalization USD 4.1 billion
Baxter International (NYSE, USD): minus 1.86 percent, P/E minus 12.40, market capitalization USD 13.1 billion
Becton, Dickinson and Company (NYSE, USD): minus 1.04 percent, P/E 57.76, market capitalization USD 52.2 billion

What the numbers leave ahead

The central market question is whether the higher earnings outlook can narrow the gap between ICU Medical's current valuation and the analyst target. The next scheduled report on November 5, 2026 will provide the next dated checkpoint for that comparison.

ICU Medical's latest completed Nasdaq session ended at USD 162.99 on October 16, 2026 at 4:00 p.m. EDT, down 2.54 percent versus the prior close of October 15, 2026.